此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Radiation Therapy in Women With Low Risk Early-Stage Breast Cancer Who Have Undergone Breast Conservation Surgery (IMPORT)

Randomised Trial Testing Intensity Modulated and Partial Organ Radiotherapy After Breast Conservation Surgery for Early Breast Cancer

RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Giving radiation therapy after surgery may kill any tumor cells that remain after surgery. It is not yet known whether intensity-modulated radiation therapy is more effective than standard radiation therapy in treating patients with early-stage breast cancer.

PURPOSE: This randomized phase III trial is comparing radiation therapy regimens in treating women with early-stage breast cancer who have undergone breast-conservation surgery.

研究概览

地位

未知

条件

详细说明

OBJECTIVES:

  • To test partial breast radiotherapy using intensity-modulated techniques following complete local tumor excision in women with low-risk, early stage breast cancer.

OUTLINE: This is a multicenter study.

Patients are stratified according to center (not participating in sub-studies vs participating in sub-studies). Patients are randomized to 1 of 3 treatment arms.

  • Arm I (control): Patients undergo standard whole breast radiotherapy once daily on days 1-5 (15 fractions) for 3 weeks.
  • Arm II: Patients undergo reduced whole breast radiotherapy (15 fractions) and standard partial breast radiotherapy (15 fractions) once daily on days 1-5 for 3 weeks.
  • Arm III: Patients undergo standard partial breast radiotherapy once daily on days 1-5 (15 fractions) for 3 weeks.

All patients complete a family history questionnaire at baseline. Patients also undergo blood sample collection at baseline and paraffin-embedded tissue collection at follow-up for molecular studies analyzing inter-patient variation by microarrays.

Patients in centers participating in sub-studies undergo quality of life and health economic assessment at baseline, 6 months, and 1, 2, and 5 years. These patients also undergo photographic assessment at baseline, 2 years, and 5 years.

After completion of study treatment, patients are followed for 10 years.

研究类型

介入性

注册 (实际的)

2018

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • England
      • Sutton、England、英国、SM2 5PT
        • Royal Marsden - Surrey

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

50年 及以上 (成人、年长者)

接受健康志愿者

有资格学习的性别

女性

描述

DISEASE CHARACTERISTICS:

  • Diagnosis of low-risk early stage breast cancer, meeting the following criteria:

    • Invasive adenocarcinoma

      • No invasive carcinoma of classical lobular type
      • lympho-vascular invasion present or absent
    • Tumor size pathologically determined to be ≤ 3.0 cm in diameter (pT1-2) (< 3.1 cm maximum microscopic diameter of invasive component)
    • Unifocal disease
    • Grade I, II, or III disease
    • Axillary lymph nodes negative or 1-3 nodes positive (pN0 or pN+(1-3))
  • Must have undergone breast conservation surgery with or without adjuvant systemic therapy

    • Minimum microscopic margin of non-cancerous tissue ≥ 2 mm (excluding deep margin if this is at deep fascia)
  • At low risk of local recurrence after radiotherapy (< 1% annual risk local recurrence)
  • No prior mastectomy
  • No blood-borne metastases

PATIENT CHARACTERISTICS:

  • No prior malignancy except nonmelanoma skin cancer

PRIOR CONCURRENT THERAPY:

  • See Disease Characteristics
  • No prior endocrine therapy or chemotherapy

    • Neoadjuvant endocrine therapy allowed provided the tumour is < 3.0 cm and all other inclusion criteria are met
    • No primary endocrine therapy as a replacement for surgery
  • No concurrent chemoradiotherapy

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
有源比较器:Arm I (control)
Patients undergo standard whole breast radiotherapy once daily on days 1-5 for 3 weeks.
Patients undergo standard whole breast, reduced whole breast, or standard partial breast radiotherapy
实验性的:Arm II
Patients undergo reduced whole breast radiotherapy and standard partial breast radiotherapy once daily on days 1-5 for 3 weeks.
Patients undergo standard whole breast, reduced whole breast, or standard partial breast radiotherapy
实验性的:Arm III
Patients undergo standard partial breast radiotherapy once daily on days 1-5 for 3 weeks.
Patients undergo standard whole breast, reduced whole breast, or standard partial breast radiotherapy

研究衡量的是什么?

主要结果指标

结果测量
大体时间
Local tumor control in the ipsilateral breast (i.e., true recurrence plus new primary tumor) as confirmed by cytological or histological assessment
大体时间:5 years
5 years

次要结果测量

结果测量
大体时间
Location of tumor relapse
大体时间:5 years
5 years
Contralateral primary breast cancer or other primary tumors as confirmed by cytological or histological assessment
大体时间:5 years
5 years
Regional and distant metastases
大体时间:5 years
5 years
Late adverse effects in normal tissue normal tissues as determined periodically by photographic assessments (in a subset of patients), physician assessments, and patient self-assessments
大体时间:5 years
5 years
Quality of life as assessed by EORTC QLQ C-30, EORTC QLQ-BR23, BIS, and HADS questionnaires in a subset of patients at baseline, 6 months, and 1, 2, and 5 years
大体时间:5 years
5 years
Cost-effectiveness as assessed by EQ-5D questionnaire at baseline, 6 months, and 1, 2, and 5 years
大体时间:10 years
10 years

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

合作者

调查人员

  • 首席研究员:Charlotte E Coles, PhD、University of Cambrige, England

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2007年5月3日

初级完成 (实际的)

2016年6月15日

研究完成 (预期的)

2020年9月1日

研究注册日期

首次提交

2008年12月24日

首先提交符合 QC 标准的

2008年12月24日

首次发布 (估计)

2008年12月25日

研究记录更新

最后更新发布 (实际的)

2019年2月27日

上次提交的符合 QC 标准的更新

2019年2月26日

最后验证

2019年2月1日

更多信息

与本研究相关的术语

其他研究编号

  • CDR0000629768
  • NIHR 2253 (其他标识符:NIHR)
  • ICR-CTSU/2006/10001 (其他标识符:ICR-CTSU)
  • ISRCTN12852634 (注册表标识符:ISRCTN)
  • CRUK/06/003 (其他赠款/资助编号:Cancer Research UK)
  • 06/Q1605/128 (其他标识符:Main Research Ethics Committee)

药物和器械信息、研究文件

研究美国 FDA 监管的药品

研究美国 FDA 监管的设备产品

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

radiation therapy的临床试验

3
订阅